Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy, Glucagon-Like Peptide 1
Conditions
Brief summary
Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, may hold promise in preventing the onset and progression of diabetic kidney disease. However, the potential renoprotective effects of these agents, that are believed to be effectuated beyond glucose control, have not been sufficiently detailed in human diabetes. Therefore, the present study aims to explore the mechanistic and clinical effects of GLP-1 receptor agonists on renal physiology and biomarkers in patients with type 2 diabetes. Forty patients with insulin-treated type 2 diabetes will undergo an eight week intervention with lixisenatide or insulin glulisine in order to assess changes in the outcome parameters.
Interventions
DRUGLixisenatide
GLP-1 receptor agonist
DRUGInsulin glulisine
Insulin analogue
Sponsors
Amsterdam UMC, location VUmc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with type 2 diabetes (HbA1c: 6.5-10.0% or 48-86 mmol/mol) * Stable treatment with basal insulin glargine (dose ±20%) and metformin or basal insulin glargine (dose ±20%) alone for at least 3 months * Fasting plasma glucose \<10 mmol/L or the use of \>50 units of basal insulin glargine * Females must be post-menopausal * Caucasian * Age: 35 - 75 years * Body Mass Index: \>25 kg/m2 * Hypertension should be under control, i.e. \<140/90 mmHg, and treated with an angiotensin-converting enzyme inhibitor or angiotensin-II-receptor blocker for at least 3 months. * Albuminuria should be treated with an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin-II-receptor blocker (ARB) for at least 3 months.
Exclusion criteria
* Current/chronic use of the following medication: thiazolidinediones, sulfonylurea derivatives, GLP-1 receptor agonists, dipeptidyl peptidase (DPP)-4 inhibitors, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics, antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors. Subjects on diuretics, will only be excluded when these drugs cannot be stopped for the duration of the study. * Chronic use of non-steroidal anti-inflammatory drugs will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, head-ache or back ache). However, no such drugs can be taken within a time-frame of 2 weeks prior to renal-testing * Hypoglycemia unawareness based on investigator judgment * History of severe hypoglycemia that required emergency hospital treatment within 3 months prior to screening * Estimated GFR \<60 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation) * Pregnancy * Current urinary tract infection and active nephritis * Recent (\<6 months) history of cardiovascular disease, including: acute coronary syndrome, chronic heart failure (New York Heart Association grade II-IV), stroke or transient ischemic neurologic disorder * Complaints compatible with or established gastroparesis, neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan) * Active liver disease or a 3-fold elevation of liver enzymes (aspartate aminotransferase/alanine aminotransferase) at screening * History of or actual pancreatic disease * History of or actual malignancy (except basal cell carcinoma) * History of or actual severe mental disease * Substance abuse (alcohol: defined as \>4 units/day) * Allergy to any of the agents used in the study * Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study * Inability to understand the study protocol or give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF) | 8 weeks | ml/min |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Renal damage, measured by urine biomarkers | 8 weeks | enzyme immuno assay |
| Renal tubular function | 8 weeks | e.g. percentage (%) |
| Blood Pressure | 8 weeks | mmHg |
Other
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory markers | 8 weeks | e.g. nmol/l |
| Systemic hemodynamic variables | 8 weeks | e.g. ml/min |
| Body anthropometrics: body weight, height, body mass index, waist circumference | 8 weeks | kilogram, meters, centimeters |
| Microvascular function | 8 weeks | e.g. count |
| Arterial stiffness | 8 weeks | e.g. augmentation index |
| Heart rate | 8 weeks | beat per minute |
| Body fat content | 8 weeks | e.g. percentage (%) |
| Glycemic variables | 8 weeks | e.g. mmol/l, mmol/mol |
| Lipid spectrum | 8 weeks | e.g. mmol/l |
Countries
Netherlands
Outcome results
None listed